Drugs / Teripulimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05737563 | Feb 2023 → Feb 2026 | esophageal squamous cell carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teripulimab | “Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.” NCT05737563 ↗ |
| Route | Other | “Teripulimab 240mg, injection” NCT05737563 ↗ |